Inspire Medical Posts Q3 Loss, Revenue Beats Estimates
The Golden Valley, Minnesota, sleep apnea device maker reported a third-quarter net loss while adjusted earnings and revenue topped analyst estimates.
Updated on Nov. 3, 2026 in Sleep Disorders
Inspire Medical Systems reported a third-quarter loss of $24.4 million, or 84 cents per share, on Monday. Adjusted earnings excluding restructuring and non-recurring costs were 14 cents per share, and third-quarter revenue reached $206.7 million.
Why it matters
The results show revenue and adjusted earnings coming in above Zacks analyst averages despite a reported net loss. Investors and patients tracking treatment access for obstructive sleep apnea have a clearer read on the company's near-term financial trajectory in Minnesota and beyond.
Inspire's third-quarter adjusted earnings of 14 cents per share exceeded the Zacks analyst average of 10 cents, and revenue of $206.7 million topped the $204.3 million estimate. The company's reported loss of 84 cents per share reflects restructuring and non-recurring costs that were excluded from the adjusted figure, and the source does not detail their size or timing.
The players
Inspire Medical Systems Inc.
A medical device company based in Golden Valley, Minnesota, that makes implantable therapy for obstructive sleep apnea.
The details
Inspire Medical Systems Inc., which manufactures devices for treating obstructive sleep apnea, announced the results on Monday. The company also projected full-year earnings of $1.20 to $1.40 per share and full-year revenue of $850 million to $860 million.
Timeline
Monday, November 2, 2026: Inspire reports third-quarter results.
Sleep Apnea Treatment Market
Inspire's results are measured against Zacks analyst consensus, and the company beat both the earnings and revenue benchmarks. The figures place the company's performance in the context of the implantable sleep apnea therapy segment, where it competes as a specialized device maker.
Patients with obstructive sleep apnea who track device availability may find the company's revenue outlook informative about its operational stability. The source does not indicate any change to treatment access, pricing, or insurance coverage for patients.
The takeaway
Revenue and adjusted earnings beating analyst estimates suggest the company is executing ahead of consensus expectations even while reporting a net loss. Readers following sleep apnea care should watch whether the full-year guidance holds in coming quarters.
Further reading
For more on treatment options, see Sleep Disorders coverage.
